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Abstract
Background: High-density lipoproteins (HDL) and their main apolipoprotein, apoA-I, exhibit anti-inflammatory
properties. The development of peptides that mimic HDL apolipoproteins offers a promising strategy to reduce
inflammatory disease. This study aimed to compare the anti-inflammatory effects of ETC-642, an apoA-I mimetic
peptide, with that of discoidal reconstituted HDL (rHDL), consisting of full-length apoA-I complexed with
phosphatidylcholine, in rabbits with chronic vascular inflammation.
Results: New Zealand White rabbits (n = 10/group) were placed on chow supplemented with 0.2% (w/w)
cholesterol for 6-weeks. The animals received two infusions of saline, rHDL (8 mg/kg apoA-I) or ETC-642 (30 mg/kg
peptide) on the third and fifth days of the final week. The infusions of rHDL and ETC-642 were able to significantly
reduce cholesterol-induced expression of intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) in the thoracic aorta (p < 0.05). When isolated rabbit HDL was pre-incubated with human
coronary artery endothelial cells (HCAECs), prior to stimulation with TNF-a, it was found that HDL from ETC-642
treated rabbits were more effective at inhibiting the TNF-a-induced increase in ICAM-1, VCAM-1 and p65 than HDL
isolated from saline treated rabbits (p < 0.05). There were, however, no changes in HDL lipid composition between
treatment groups.
Conclusions: Infusion of ETC-642 causes anti-inflammatory effects that are comparable to rHDL in an animal
model of chronic vascular inflammation and highlights that apoA-I mimetic peptides present a viable strategy for
the treatment of inflammatory disease.
Keywords: High-density lipoproteins, apolipoproteinA-I, apolipoproteinA-I mimetic peptides, vascular inflammation,
rabbits, intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)
Background
An increase in the endothelial cell expression of adhe-
sion molecules such as vascular cell adhesion molecule-
1 (VCAM-1) and intercellular adhesion molecule-1
(ICAM-1) is characteristic of the initial inflammatory
response triggered by endothelial damage or dysfunction
[1]. Elevated expression of adhesion molecules promotes
the recruitment and trans-endothelial migration of
circulating monocytes into the artery wall, eventually
leading to the development of atherosclerosis [1].
The anti-inflammatory properties of high-density lipo-
proteins (HDL) are well established [2]. In vitro studies
have demonstrated that reconstituted (rHDL), contain-
ing apolipoprotein (apo) A-I (the main apolipoprotein
constituent of HDL) complexed with phospholipids,
inhibit the expression of VCAM-1 and ICAM-1 in
human umbilical vein endothelial cells [3-6]. Consistent
with this, in vivo studies in rabbits also show that lipid
free apoA-I and rHDL reduce the expression of arterial
VCAM-1 and ICAM-1 in the peri-arterial cuff model of
acute inflammation [3,7,8]. Due to their potent anti-
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immense therapeutic potential, but despite this there is
currently no translated use to clinic.
The limiting factor in the therapeutic usefulness of
apoA-I is its relatively large size of 243 amino acids,
thereby making its synthesis difficult. This has lead to
the development of apoA-I mimetic peptides that are
much shorter in length (18-22 peptides) and able to be
readily synthesized on a large scale, but still exhibit the
same beneficial properties as HDL and full-length apoA-
I. For example, infusions of mimetic peptides reduce
atherosclerotic lesion size, improve endothelial dysfunc-
tion and also inhibit VCAM-1 and ICAM-1 expression
in vitro and in vivo [9-13]. The apoA-I mimetic peptide
used in our study, ETC-642, consists of a 22-amino acid
synthetic amphipathic peptide complexed with sphingo-
myelin and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC) [14,15]. Recent studies have found that ETC-
642 is as effective as rHDL at suppressing acute inflam-
mation in the rabbit peri-arterial collar model [16]. The
anti-inflammatory effects of ETC-642 on chronic inflam-
mation are, however, currently unknown.
Accordingly, this study has investigated the effect of
ETC-642 on low-grade chronic vascular inflammation,
in cholesterol-fed New Zealand White (NZW) rabbits
[17,18]. We find that ETC-642 reduced the expression
of VCAM-1 and ICAM-1 in the rabbit thoracic aorta to
a similar extent as rHDL containing full-length apoA-I.
These studies highlight the efficacy and therapeutic
potential of mimetic peptides in the treatment of inflam-
mation and cardiovascular disease.
Results
Effects of the dietary intervention on plasma lipids
The concentrations of plasma total cholesterol, HDL
cholesterol and non-HDL are presented in Table 1.
Consumption of a chow diet supplemented with 0.2%
cholesterol for 6 weeks significantly increased total cho-
lesterol concentrations (~3 fold) in all treatment groups
(p < 0.01). At sacrifice, there were no differences in
plasma total cholesterol between the control animals
and those receiving infusions of rHDL or ETC-642.
HDL cholesterol levels were not altered after six weeks
of cholesterol feeding. Treatment with rHDL or ETC-
642 did not change HDL cholesterol levels, compared to
saline infused rabbits, at the time of sacrifice.
Non-HDL cholesterol levels were significantly
increased (p < 0.05) with cholesterol feeding in rabbits
injected with saline (22-fold), rHDL (9-fold) or ETC-642
(8.5 fold) (p < 0.05 for all). However, at the time of
sacrifice there were no significant differences in non-
HDL cholesterol concentrations between treatment
groups.
Effect of rHDL and ETC-642 on chronic vascular
inflammation
The ability of rHDL and ETC-642 to reduce cholesterol-
induced inflammation in the thoracic aorta was deter-
mined by measuring endothelial ICAM-1 and VCAM-1
expression (Figure 1). After six weeks of cholesterol
feeding endothelial ICAM-1 expression was at readily
detectable levels in rabbits infused with saline. In rabbits
infused with rHDL, ICAM-1 expression was reduced by
58% (p < 0.05). The ETC-642 infusions were as effective
as rHDL and reduced endothelial ICAM-1 expression by
53% (p < 0.05). EndothelialV C A M - 1e x p r e s s i o nw a s
increased to detectable levels following 6 weeks of cho-
lesterol feeding. Two infusions of rHDL or ETC-642 in
the final week of cholesterol feeding were found to
reduce VCAM-1 by 73% and 76% respectively (p < 0.05).
After six weeks of cholesterol feeding there were no
signs of fatty streak formation and therefore macro-
phages were not detected in the immuno-histochemi-
cally stained thoracic aortic sections.
Effect of ETC-642 on the anti-inflammatory properties and
composition of rabbit HDL
HDL were isolated from the rabbits that were infused
with saline, rHDL and ETC-642 and assessed for their
ability to inhibit TNF-a-induced expression of ICAM-1
and VCAM-1 in HCAECs (Figure 2). As expected, sti-
mulation of HCAECs with TNF-a increased ICAM-1
(17.2 fold) and VCAM-1 (50.6 fold) mRNA levels, com-
pared to un-stimulated control cells (p < 0.001). When
the cells were pre-incubated for 24 hrs with rHDL, the
Table 1 Effects of saline, rHDL and ETC-642 infusions on plasma lipid levels in NZW rabbits
BASELINE TIME OF SACRIFICE
TC
(mM/L)
HDL-C
(mM/L)
Non HDL-C
(mM/L)
TC
(mM/L)
HDL-C
(mM/L)
Non HDL-C
(mM/L)
SALINE 0.86 ± 0.07 0.77 ± 0.09 0.09 ± 0.07 2.64 ± 0.29* 0.65 ± 0.03 1.99 ± 0.28*
rHDL 0.84 ± 0.06 0.63 ± 0.06 0.21 ± 0.06 2.53 ± 0.49* 0.66 ± 0.06 1.87 ± 0.46*
ETC-642 0.99 ± 0.05 0.73 ± 0.04 0.26 ± 0.06 2.87 ± 0.27* 0.61 ± 0.05 2.25 ± 0.26*
NZW rabbits (n = 10/group) were maintained on a diet of chow supplemented with 0.2% (w/w) cholesterol for 6 weeks On days 3 and 5 of the last week of
dietary supplementation the animals received two infusions of saline, rHDL (8 mg/kg apoA-I) or ETC-642 (30 mg/kg peptide). Blood samples were collected at
baseline and at sacrifice and plasma lipid levels were measured as described in “Materials and Methods”. Results are expressed as mean ± SEM. * p < 0.05
compared to baseline.
Di Bartolo et al. Lipids in Health and Disease 2011, 10:224
http://www.lipidworld.com/content/10/1/224
Page 2 of 8TNF-a-mediated increase in ICAM-1 and VCAM-1
mRNA levels was reduced by 35.5 ± 19.4% (p < 0.05)
and 73.8 ± 8.4% (p < 0.001), respectively. We found that
pre-incubation of cells with HDL from ETC-642
injected rabbits, caused reductions in TNF-a-induced
ICAM-1 (17.4 ± 3.0%) and VCAM-1 (27.1 ± 15.0%)
mRNA levels (p < 0.05). HCAECs incubated with HDL
isolated from rabbits injected with saline and rHDL also
expressed lower levels of ICAM-1 and VCAM-1 mRNA,
compared to TNF-a stimulated controls, but these
reductions did not reach statistical significance.
Changes in the mRNA levels of p65, the active subunit
of NF-B, were also measured, as it is a known regula-
tor of ICAM-1 and VCAM-1 expression. Stimulation of
HCAECs with TNF-a increased p65 mRNA levels (1.5
fold), compared to un-stimulated control cells (p <
0.01). When cells were pre-incubated for 24 hrs with
rHDL, the TNF-a-mediated increase in p65 mRNA
levels was reduced by 36.0 ± 13.4% (p < 0.05). We
found that pre-incubation of cells with HDL from
rabbits injected with saline and ETC-642 caused
reduced TNF-a-induced p65 mRNA levels, by 21.4 ±
10.8% and 31.0 ± 4.3% respectively (p < 0.05). Pre-incu-
bation with HDL from the rabbits that received rHDL
did not inhibit p65 mRNA levels.
Infusion of rHDL or ETC-642 did not significantly
affect the composition of HDL. The relative concentra-
tions of phospholipid, unesterified cholesterol, choles-
terol ester and triglyceride were not statistically different
from what was observed for HDL isolated from rabbits
infused with saline (Table 2).
Discussion
The development of apoA-I mimetic peptides has pro-
vided much therapeutic promise for the treatment of
inflammatory and cardiovascular diseases. ETC-642 is a
22 amino acid peptide that mimics the structure of the
amphipathic a-helices of apoA-I when combined with
lipids. We therefore compared its ability to inhibit
chronic vascular inflammation in cholesterol-fed rabbits,
ICAM-1 VCAM-1 
SALINE 
rHDL 
8 mg/kg
ETC-642 
30 mg/kg 
*  * 
*  * 
ICAM-1 
VCAM-1 
Panel A  Panel B 
Figure 1 ETC-642 reduces endothelial adhesion molecule expression. Panel A: Immunohistochemical staining for ICAM-1 and VCAM-1 in
representative thoracic aortic sections from cholesterol-fed NZW rabbits (n = 10 animals/group) infused with either saline, rHDL (8 mg/kg apoA-
I) or ETC-642 (30 mg/kg peptide). Panel B: Endothelial expression of ICAM-1 and VCAM-1 were quantified as described in “Materials and
Methods”. Results are expressed as mean ± SEM. *p < 0.05 and **p < 0.01, compared to saline-infused animals.
Di Bartolo et al. Lipids in Health and Disease 2011, 10:224
http://www.lipidworld.com/content/10/1/224
Page 3 of 8with that of rHDL (containing apoA-I and PLPC). We
find, for the first time, that the mimetic peptide ETC-
642 inhibits adhesion molecule expression in this model.
Furthermore, HDL isolated from rabbits injected with
ETC-642 displays more potent anti-inflammatory prop-
erties than HDL isolated from rabbits injected with sal-
ine or rHDL.
Increased expression of adhesion molecules VCAM-1
and ICAM-1, represent the earliest vasculature altera-
tion following the initiation of an atherogenic diet
[17,18]. Using a cholesterol-fed rabbit model, vascular
inflammation develops gradually via a process that is
somewhat comparable to early human lesion develop-
ment [17]. In this model we have demonstrated that
infusions of rHDL were able to significantly attenuate
cholesterol-induced aortic expression of VCAM-1 and
ICAM-1. These findings support the numerous in vitro
studies that demonstrate the anti-inflammatory proper-
ties of rHDL and in vivo studies showing that rHDL and
apoA-I inhibit acute vascular inflammation [3,6,13,19].
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Figure 2 The effect of isolated rabbit HDL on adhesion molecule expression and NF-B activation in HCAECs.H C A E C sw e r ep r e -
incubated for 24 hrs with rHDL or HDL isolated from the plasma of rabbits injected with either saline, rHDL or ETC-642 (n = 10), then stimulated
with TNF-a (1 ng/ml) for 5 hrs. ICAM-1, VCAM-1 and p65 mRNA levels were quantified as described in “Materials and Methods”. Results
expressed as mean ± SEM from triplicate in vitro experiments. *p < 0.05 and **p < 0.01, compared to TNF-a stimulated control cells.
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mimetic peptide ETC-642 can inhibit adhesion molecule
expression in a model of chronic vascular inflammation.
Our findings are also consistent with previous studies
that have used ETC-642 and shown that it inhibits the
development of similar inflammatory pathologies such
as acute inflammation in the carotid artery in the rabbit
peri-arterial collar model [16], cholesterol-induced aortic
valve stenosis [20] and atherosclerosis in apoE
-/- mice
[21].
The beneficial cardio-protective properties of HDL
have been attributed to their ability to efflux cholesterol
from cells, including endothelial cells [22,23]. Several
studies have demonstrated that apoA-I mimetic peptides
are also able to stimulate cholesterol efflux [13,24]. For
example, infusions of ETC-642 transiently elevate cho-
lesterol levels in rats and humans [20,25], indicating
enhanced mobilization of cell cholesterol into the
plasma. Enhanced cholesterol efflux may provide a
mechanism for the anti-inflammatory effects of ETC-
642, as has been demonstrated by other mimetic pep-
tides [13]. In the current study, however, we found that
ETC-642 had no effect on plasma total cholesterol or
HDL cholesterol concentrations at the time of sacrifice.
The reason for this is likely to be that the final ETC-642
injection was 48 hours prior to sacrifice. As the choles-
terol elevating properties of ETC-642 occur within 45
minutes after infusion [20], the lack of change at 48 h
post-infusion is therefore to be expected [16]. This may
also explain why HDL composition did not change fol-
lowing rHDL and ETC-642 infusions and confirms our
recent work, which showed that injection of lipid free
apoA-I and rHDL increased HDL phospholipid, unester-
ified cholesterol and cholesterol ester levels at 5 min-
utes, but not at 6 h after infusion [26].
Despite the lack of apparent compositional change in
rabbit HDL between treatment groups, the HDL from
rabbits infused with ETC-642 appeared to exert more
potent anti-inflammatory effects ex vivo in HCAECs
than the HDL from rabbits injected with saline or
rHDL. Recent proteomic studies have identified multiple
proteins that co-isolate with human HDL [27,28],
including for example antioxidants, protease inhibitors
and growth factors. These HDL-associated proteins are
likely to impart some of the beneficial physiological
effects of HDL [27]. Changes in the presence of these
HDL-associated proteins are also likely to alter HDL
function. It is possible that whilst the ETC-642 infusions
did not significantly alter the relative amounts of phos-
pholipids, unesterified cholesterol, esterified cholesterol
or triglycerides, it may have changed the protein compo-
sition of the rabbit HDL in a way that increased their
anti-inflammatory properties. Interestingly, the HDL
from ETC-642 injected mice were also able to reduce
the protein levels of the active subunit of NF-B, p65.
This reduction in p65 provides a possible mechanism
for the reductions in both VCAM-1 and ICAM-1 as
they are both regulated via activation of the NF-B
pathway [29,30]. This is also consistent with a number
of studies showing that HDL and rHDL reduce NF-B
activation and the expression of p65 [6,13,31].
The current study demonstrated that infusions of
rHDL and ETC-642 inhibit the initial inflammatory
response. This suggests that rHDL and ETC-642 may
also attenuate the next stages of atherosclerotic lesion
development. In support of this, previous work by our
group and others has demonstrated that rHDL reduces
lesion size and macrophage content in rabbits and mice
[19,32,33]. Furthermore, adenoviral gene transfer of
ETC-642 has been shown to decrease atherosclerosis in
apoE
-/- mice [21].
Conclusions
Using a cholesterol-fed rabbit model of chronic vascular
inflammation we have demonstrated that mimetic pep-
tide ETC-642 inhibits endothelial expression of adhesion
molecules, markers of the earliest stages of atherosclero-
sis. These studies provide additional support for the
therapeutic efficacy of mimetic peptides in the treatment
of inflammation and cardiovascular disease.
Methods
Isolation of rabbit HDL and apolipoprotein A-I
Rabbit HDL were isolated from rabbit plasma (100 ml)
by sequential ultracentrifugation in the 1.063 < d < 1.21
g/ml density range [34] and dialyzed against endotoxin-
free phosphate buffered saline (PBS). Human HDL were
isolated from pooled samples of autologously donated
human plasma (Gribbles Pathology, South Australia) by
sequential ultracentrifugation in the same density range.
The human HDL were delipidated and apoA-I isolated
by anion chromatography [34].
Table 2 Effects of saline, rHDL and ETC-642 infusions on
HDL composition
Infusion Stoichiometry
PL
a/UC/CE/TG/Protein
(mol/mol)
Saline 27.0 ± 6.8/10.5 ± 1.0/24.0 ± 1.3/1.3 ± 0.2/1.0
rHDL 33.5 ± 6.6/7.9 ± 0.9/21.8 ± 1.1/1.8 ± 0.4/1.0
ETC-642 32.5 ± 10.2/10.8 ± 1.0/22.1 ± 2.0/1.4 ± 0.3/1.0
NZW rabbits (n = 10/group) were maintained on a diet of chow
supplemented with 0.2% (w/w) cholesterol for 6 weeks. On days 3 and 5 of
the last week of dietary supplementation the animals received two infusions
of saline, rHDL (8 mg/kg apoA-I) or ETC-642 (30 mg/kg peptide). Blood was
collected at sacrifice and HDL were isolated and their composition
determined as described in “Materials and Methods”. Results are expressed as
mean ± SEM.
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Discoidal rHDL containing apoA-I complexed to 1-pal-
mitoyl-2-linoleoyl phosphatidylcholine (PLPC) (Avanti
Polar Lipids, Alabaster, AL, USA) (initial PLPC/apoA-I
molar ratio 100:1). were prepared using the cholate dia-
lysis method [35]. The resulting rHDL were dialysed
extensively against endotoxin-free PBS (pH 7.4) before
use.
Preparation of ETC-642
The ETC-642 was provided as a lyophilized solid by Esper-
ion Therapeutics, Pfizer (Groton, MI, USA). The complex
consists of ESP-2418, an amphipathic peptide containing
22 L-amino acid residues: P-V-L-D-L-F-R-E-L-L-N-E-L-L-
E-A-L-K-Q-K-L-K with a molecular weight of 2623 dal-
tons that is complexed to sphingomyelin and 1,2-dipalmi-
toyl-sn-glycero-3-phosphocholine (DPPC) (peptide/
sphingomyelin/DPPC molar ratio 1/3.75/3.75. The lyophi-
lized solid was rehydrated with 50 ml of a sterile bicarbo-
nate saline solution (Esperion Therapeutics, Pfizer,
Groton, CT, USA) and gently swirled to mix. Three cycles
of warming at 50°C and cooling to room temperature
were performed to ensure complete reconstitution. The
final protein concentration of ETC-642 was 10 mg/ml and
the peptide was stored at 4°C until use.
Animal Experiments
The Sydney South West Area Health Service Animal
Welfare Committee approved all animal procedures.
Thirty male NZW rabbits weighing approximately 3 kg
were obtained from the Institute of Medical and Veterin-
ary Sciences (Adelaide, South Australia). Following a
seven-day acclimatisation period, baseline plasma choles-
terol and HDL levels were determined prior to placing
the animals on a diet of normal chow supplemented with
0.2% (w/w) cholesterol for 6 weeks. Five weeks after com-
mencement of the diet, the rabbits were randomised into
three treatment groups (n = 10/group). A blood sample
(3 mL) was collected from each animal at this time point.
Plasma cholesterol levels were then determined to con-
firm that there were no significant differences between
treatment groups. The animals then received two intrave-
nous infusions of saline (control group), rHDL (8 mg/kg
apoA-I) or ETC-642 (30 mg/kg peptide) on the third and
fifth days of the final (sixth) week of dietary intervention
and were sacrificed at the end of the sixth week of high
cholesterol feeding. The animals were euthanased with
an intravenous overdose of sodium pentobarbital (100
mg/kg). Plasma was collected via cardiac puncture. The
thoracic aortae were then removed, flushed with chilled
PBS before placement in cold 4% (v/v) paraformaldehyde
overnight. The aortae were then transferred to 70% (v/v)
ethanol and stored at 4°C, then paraffin embedded for
histological analysis.
Immunohistochemistry
Sections (5 mm) of the paraffin-embedded vessels were
cut, dewaxed, and rehydrated. Mouse anti-rabbit
VCAM-1 and ICAM-1 antibodies (gifts from Dr M
Cybulsky, University of Toronto) were used to assess
endothelial expression of adhesion molecules in the
thoracic aorta. For the assessment of macrophages, thor-
acic aortic sections were stained for RAM11 (1:100;
Dako). Thoracic aortic sections (10 sections/rabbit) were
analysed using ImagePro Plus 4.5 (Media Cybernetics,
Silver Spring, MD) as described [3,19]. Image analysis
results are expressed as image units.
Plasma Analyses and HDL composition
Total cholesterol concentrations were determined on
rabbit plasma and isolated rabbit HDL enzymatically
using commercially availablek i t s( R o c h eD i a g n o s t i c s ) .
HDL cholesterol concentrations were determined on
rabbit plasma by enzymatic assay following precipitation
of apolipoprotein B containing lipoproteins with poly-
ethylene glycol [36]. Phospholipid, unesterified choles-
terol, cholesterol ester and triglyceride concentrations
were assessed in rabbit HDL also using commercially
available kits (Wako Pure Chemicals).
Endothelial cell culture
Human coronary artery endothelial cells (HCAECs)
w e r eg r o w ni nM e s o E n d oc e l lc u l t u r em e d i u m( C e l l
Applications Inc., CA, USA) and seeded at 1 × 10
6 cells/
well in 12-well plates. Cells were then treated for 24 h
with PBS, rHDL (1 mg/ml final apoA-I concentration)
or isolated rabbit HDL (1 mg/ml final protein concen-
tration). Following this cells were washed 1× with PBS
and then stimulated with tumor necrosis factor-a (TNF-
a) (1 ng/ml). After 5 h the cells were harvested and
stored at -80°C until required.
Real-time PCR
Total RNA was extracted using the Trizol method,
quantitated and normalised to 100 ng/uL using SYBR
Green II assay (Invitrogen). RNA was then reverse tran-
scribed in triplicate to cDNA using iSCRIPT (BioRad).
Real-time PCR was performed in triplicate using
iQSYBR Green Supermix (BioRad) and an iCycler iQ
Real-time thermocycler (BioRad). The threshold cycle
was calculated using iCycler iQ Real-time PCR detection
system software version 3.0A (BioRad). Relative changes
in mRNA expression between treatments were deter-
mined using the cT method. Results were normalised
using GAPDH.
Statistical Analyses
All results are expressed as mean ± SEM. Statistical
comparisons were made by two-tailed Student’st - t e s t s
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using GraphPad Prism Version 4.0 (San Diego, CA). A
value of p < 0.05 was considered statistically significant.
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